CoV-AbDab: the coronavirus antibody database
Top Cited Papers
- 17 August 2020
- journal article
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 37 (5), 734-735
- https://doi.org/10.1093/bioinformatics/btaa739
Abstract
Motivation: The emergence of a novel strain of betacoronavirus, SARS-CoV-2, has led to a pandemic that has been associated with over 700 000 deaths as of August 5, 2020. Research is ongoing around the world to create vaccines and therapies to minimize rates of disease spread and mortality. Crucial to these efforts are molecular characterizations of neutralizing antibodies to SARS-CoV-2. Such antibodies would be valuable for measuring vaccine efficacy, diagnosing exposure and developing effective biotherapeutics. Here, we describe our new database, CoV-AbDab, which already contains data on over 1400 published/patented antibodies and nanobodies known to bind to at least one betacoronavirus. This database is the first consolidation of antibodies known to bind SARS-CoV-2 as well as other betacoronaviruses such as SARS-CoV-1 and MERS-CoV. It contains relevant metadata including evidence of cross-neutralization, antibody/nanobody origin, full variable domain sequence (where available) and germline assignments, epitope region, links to relevant PDB entries, homology models and source literature. Results: On August 5, 2020, CoV-AbDab referenced sequence information on 1402 anti-coronavirus antibodies and nanobodies, spanning 66 papers and 21 patents. Of these, 1131 bind to SARS-CoV-2. Availabilityand implementation: CoV-AbDab is free to access and download without registration at http://opig.stats.ox.ac.uk/webapps/coronavirus. Community submissions are encouraged. Supplementary information: Supplementary data are available at Bioinformatics online.Keywords
Funding Information
- Engineering and Physical Sciences Research Council
- Medical Research Council (EP/L016044/1)
- Biotechnology and Biological Sciences Research Council (BB/M011224/1)
- GlaxoSmithKline plc
- UCB Pharma Ltd.
- AstraZeneca plc
- F. Hoffmann-La Roche AG
This publication has 12 references indexed in Scilit:
- Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19Nature Medicine, 2020
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoVScience, 2020
- Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencingCell Discovery, 2020
- The trinity of COVID-19: immunity, inflammation and interventionNature Reviews Immunology, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimationmAbs, 2016
- ANARCI: antigen receptor numbering and receptor classificationBioinformatics, 2015
- SAbDab: the structural antibody databaseNucleic Acids Research, 2013
- IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domainsDevelopmental & Comparative Immunology, 2002
- The Protein Data BankNucleic Acids Research, 2000